MYD88 and primary central nervous system lymphoma: Remarkably, the MyD88 mutation never occurs in tissue biopsies from nonhematologic brain tumors, such as a glioblastoma, or in solid metastatic tumors, suggesting it is a sensitive and specific biomarker for the differentiation of primary central nervous system lymphoma from other CNS cancers [67].